Fisogatinib

N/A

Report date: 2022/05/30 09:49:33
NME

Base Information

Drug NameFisogatinib
Drug Alias NameFisogatinib - Blueprint MedicinesCS-3008BLU-554
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 4 antagonists
TargetsFibroblast growth factor receptor 4
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeTaiwan +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBlueprint Medicines Corp
China Registration ClassN/A

Develop Information

Active CompaniesCstone PharmaceuticalsCatalent San Diego IncBlueprint Medicines Corp +[4] 
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A